Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressants.

Scott C Armstrong1, Kelly L Cozza, Elisabeth A Pimentel

  • 1Center for Geriatric Psychiatry, Tuality Forest Grove Hospital, Forest Grove, Ore., 97116, USA. scott.armstrong@tuality.org

Psychosomatics
|September 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obtaining and Documenting Informed Consent: An Advanced UME Cross-Specialty, Role-Playing Skill Builder.

MedEdPORTAL : the journal of teaching and learning resources·2026
Same author

Building Faculty Performance Evaluation from the Ground-Up: Designing Tools and Gauging Acceptance.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2025
Same author

The Effectiveness of Online Experiential Learning in a Psychiatry Clerkship.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2023
Same author

Psychotropic Medication Informed Consent: A Cross-Specialty Role-Playing Skill Builder.

MedEdPORTAL : the journal of teaching and learning resources·2021
Same author

Experiential Learning Cycles as an Effective Means for Teaching Psychiatric Clinical Skills via Repeated Simulation in the Psychiatry Clerkship.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2020
Same author

Updates in Consultation-Liaison Psychiatry: 2019.

Psychosomatics·2020
Same journal

Clinical Approach to Personality Change Due to Another Medical Condition.

Psychosomatics·2021
Same journal

Clonazepam for Catatonia Incompletely Responsive to lorazepam.

Psychosomatics·2021
Same journal

Diabetic Retinopathy and Depression: A Risk Assessment.

Psychosomatics·2021
Same journal

WITHDRAWN: Psychosis: A Presentation of COVID-19?

Psychosomatics·2021
Same journal

Dermatitis Neglecta, the Cognitive Assessment, and Micronutrients.

Psychosomatics·2020
Same journal

Coronavirus and Its Implications for Psychiatry: A Rapid Review of the Early Literature.

Psychosomatics·2020
See all related articles

This review details drug-drug interactions (DDIs) for common immunosuppressants like cyclosporine and tacrolimus. Understanding these DDIs is crucial for managing patients safely due to their narrow therapeutic windows.

Area of Science:

  • Pharmacology
  • Clinical Psychiatry
  • Drug Interactions

Background:

  • Consultation-liaison psychiatrists frequently encounter immunosuppressants in tertiary care.
  • Many immunosuppressants possess narrow safety and therapeutic windows.
  • Altered serum levels due to drug-drug interactions can lead to adverse effects.

Purpose of the Study:

  • To explore drug-drug interaction (DDI) profiles of commonly used immunosuppressants.
  • To provide an in-depth analysis of specific DDI topics in a new, focused format.

Main Methods:

  • Review of drug-drug interaction profiles.
  • Focus on specific immunosuppressant medications: cyclosporine, tacrolimus, sirolimus, and corticosteroids.

Main Results:

Related Experiment Videos

  • Detailed examination of DDIs associated with cyclosporine.
  • Analysis of DDIs involving tacrolimus.
  • Exploration of sirolimus and corticosteroid DDIs.

Conclusions:

  • Awareness of DDIs is critical for safe and effective use of immunosuppressants.
  • This focused approach enhances understanding of specific DDI challenges.
  • Managing DDIs is essential to prevent adverse events in patients on immunosuppressive therapy.